Citius Pharmaceuticals (CTXR) Stock Forecast & Price Target

Citius Pharmaceuticals is poised for long-term success due to strong cash position with a net cash of $4.6 million and recent additional capital raised through direct offerings and credit facilities. Its flagship product, LYMPHIR, has already launched commercially with solid initial numbers and a promising market opportunity. Furthermore, the company's late-stage clinical candidates, Mino-Lok and Halo-Lido, have potential for regulatory filings, adding to the company's growth potential. The unique mechanism of action of LYMPHIR in treating r/r CTCL and its potential for market share gains over current standard-of-care therapies position the company for continued success.

Citius Pharmaceuticals is projected to have increasing revenues in the coming years, with a projected Lymphir revenue of $21M in FY2026 growing to a peak of $156M in 2031. However, this growth is heavily dependent on the success and approval of its clinical-stage pipeline, with projected risk-adjusted peak revenues of Mino-Lok at $44M and Halo-Lido at $34M. There are also potential risks associated with these products, making the company's overall risk-adjusted total revenues of $218M in FY2034 seem uncertain.